Skip to main content
Premium Trial:

Request an Annual Quote

Bass Group Buys Stake in Human Genome Sciences

Premium

ROCKVILLE, Md.--A group of investors including several members of the Bass family purchased a 14 percent stake in the genetic research firm Human Genome Sciences here this summer, according to a filing made last month with the Securities and Exchange Commission. The filing showed that between June 8 and August 8, the group bought 568,000 shares at prices ranging from $30.42 to $31.02 per share, for investment purposes. Human Genome Sciences is involved in the discovery of human and microbial genes for the prevention, detection, treatment, and cure of disease. The firm develops products both on its own and in partnership with other companies.

Filed under

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.